Whalesbook
📉 The Financial Deep Dive
Anlon Healthcare Limited has unveiled exceptional financial performance for the third quarter and first nine months of FY26, signalling robust growth and strategic expansion.
The Numbers:
For the quarter ended December 31, 2025 (Q3 FY26), Anlon Healthcare reported a 281.47% year-on-year surge in Total Income to ₹35.78 crore, up from ₹9.38 crore in Q3 FY25. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw an extraordinary 2,006.42% rise to ₹12.54 crore, a significant jump from ₹0.60 crore. The company achieved a positive Profit After Tax (PAT) of ₹5.15 crore, marking a substantial turnaround from a loss of ₹2.49 crore in the same period last year. PAT margins stood at a healthy 14.40%.
The nine-month period ended December 2025 (9M FY26) was equally impressive. Total Income grew by 69.71% YoY to ₹121.32 crore, and EBITDA increased by 114.96% YoY to ₹32.56 crore. PAT witnessed a remarkable 365.61% YoY surge to ₹18.02 crore, compared to ₹3.87 crore in 9M FY25. The PAT margin for 9M FY26 improved substantially to 14.85%, a jump of 943 basis points from 5.41% in 9M FY25.
The Quality:
The dramatic improvement in profitability is evident in the margin expansion, particularly the PAT margin for the nine-month period nearly tripling its previous year's level. This suggests improved operational efficiency and cost management, alongside strong revenue growth.
Strategic Acquisitions and Capacity Expansion:
Beyond organic growth, Anlon Healthcare is pursuing inorganic expansion. The company acquired a 67.48% stake in Apiqo Organics Private Limited for ₹5.40 crore via an all-cash deal, aiming to enhance backward integration and cost competitiveness. Additionally, agreements are in place to acquire a 56.67% controlling stake in Bizotic Lifescience for ₹3.79 crore, pending approvals. This facility is expected to provide a ready-to-operate manufacturing base for scaling up. These combined initiatives are projected to expand the consolidated manufacturing capacity to approximately 1,400–1,600 MTPA by FY26.
🚩 Risks & Outlook
Management, led by Chairman & Managing Director Mr. Punitkumar Rasadia, is confident in its R&D-led strategy and the acquisitions. They foresee a revenue CAGR of approximately 30% over the next three years and sustainable, gradual improvement in EBITDA margins. The company has built a resilient platform across diverse end-markets, including human health, veterinary, nutraceutical, personal care, and Industrial & Fine Chemicals. The primary immediate risk lies in the successful completion of regulatory approvals for the Bizotic Lifescience acquisition. Investors will watch for the integration progress and the realization of projected capacity enhancements.